1. Pink Sheet
  2. >>Drug Safety

FDA's Latest Opioid Move Aims To 'Reset The Conversation' On Benzodiazepine Combo

 
• By Brenda Sandburg

Agency says it now has enough scientific data to act on a citizen petition noting increase in overdose deaths from concomitant prescribing of two drug classes.

FDA once again held a press briefing to note a new development in its efforts to tackle opioid problems. The agency announced on Aug. 31 that it is requiring manufacturers to elevate to a black box warning the existing label warning about the risks of concomitant use of certain opioid medications and benzodiazepines.

The risks, which include extreme sleepiness, respiratory depression, coma and death, have long been known, but agency officials said recent real world data shows how frequently the two drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.